LUNG CANCER

Patrick Forde, MBBCh offers an overview of current standard-of-care treatments as well as emerging immunotherapy options for treating early-stage, resectable non-small cell lung cancer.

Expert perspectives on clinical trials investigating doublet and triplet therapy with datopotamab deruxtecan in patients with non–small cell lung cancer.

An overview of clinical trials investigating datopotamab derutecan in patients with non–small cell lung cancer.

Other considerations between KRAS targeting treatments in patients with KRAS+ mutated NSCLC.

An overview of recognizing and managing common immune-related and systemic adverse events with immune checkpoint inhibitors, chemotherapy and KRAS targeted therapies in NSCLC.

Clinical trial efficacy and safety data between KRAS G12C inhibitors that inform initial treatment selection for patients with NSCLC.

An overview of the role of KRAS G12C inhibitors in the second line and beyond for KRAS G12C mutated NSCLCs after progression on platinum-based chemotherapy.

Cinical trial data and guidelines on optimal first-line regimens for metastatic KRAS mutated lung adenocarcinoma.

Background on KRAS mutations in lung adenocarcinoma, including the prevalence, prognosis, and challenges in treating patients with NSCLC.

Sandip P. Patel, MD, offers advice to fellow oncologists and highlights unmet needs and future directions in the treatment of patients with non–small cell lung cancer.

A medical oncologist reviews the efficacy and safety outcomes from the ADAURA trial investigating osimertinib in resected EGFR-mutated NSCLC and discusses how biomarkers inform treatment selection.

Turning the focus to EGFR inhibitors, Sandip P. Patel, MD, discusses their mechanism action and the improved toxicity profile of next-generation inhibitors.

Expert perspectives on treating patients with non–small cell lung cancer, with a focus on treatment goals and patient factors that inform clinical decision-making and sequencing considerations.

A medical oncologist offers his initial impressions of the patient profile of a 60-year-old with early-stage NSCLC and discusses biomarker testing practices, highlighting types of testing and challenges.

Sandip P. Patel, MD, reviews the case of a 60-year-old woman with early-stage non–small cell lung cancer (NSCLC).

Patrick Forde, MBBCh, discusses the results of the TRIDENT-1 trial that led to the approval of repotrectinib for patients with metastatic ROS1 positive NSCLC.

Anlotinib, a novel multi-targeting tyrosine kinase inhibitor, and icotinib, a first-generation EGFR TKI, demonstrated efficacy and tolerability in the first line for the treatment of patients with EGFR-mutated advanced non–small cell lung cancer.

Edward B. Garon, MD, MS, reviews the safety profiles of sacituzumab govitecan and datopotamab deruxtecan in patients with non–small cell lung cancer.

A brief overview of clinical trials investigating datopotamab deruxtecan in patients with non–small cell lung cancer.

Anne Chiang, MD, PhD, discusses the takeaways from her presentation given at the 18th Annual New York Lung Cancers Symposium.

Antibody-based DLL3-targeting agents and antibody-drug conjugates present exciting treatment possibilities in small cell lung cancer, according to a presentation by Charles Rudin, MD, at the 18th Annual New York Lung Cancer Symposium.

The combination of vibostolimab and pembrolizumab plus docetaxel did not significantly improve progression-free survival compared with docetaxel monotherapy in patients with previously treated metastatic non–small cell lung cancer.

The phase 3 KEYLYNK-008 trial investigating pembrolizumab and olaparib in metastatic squamous non–small cell lung cancer will be stopped due to futility.

Thoracic oncologists discuss the EVOKE-02 study investigating sacituzumab govitecan in combination with pembrolizumab in patients with first-line metastatic NSCLC.

Comprehensive insights on clinical trial data that have led to further development of sacituzumab govitecan for patients with non–small cell lung cancer.

Significant findings from a number of trials in the lung cancer space will make their way into case reports.

In the second article of a 2-part series, Martin F. Dietrich, MD, PhD, discusses the results of the phase 1 CHRYSALIS study of amivantamab for patients with EGFR exon 20 insertion-mutated NSCLC.

Experts on non–small cell lung cancer discuss the role of antibody-drug conjugates and review their mechanism of action.

A review of preclinical studies looking at TROP2 expression in patients with non–small cell lung cancer.